Medtech company Zimmer Biomet recorded $2.2 billion in net sales during the second quarter of 2026, an increase of 4.8%, according to its Aug. 5 financial report.
Here are 10 things to know:
- Net sales in the U.S. totaled $1.24 billion, and international net sales accounted for $937 million in the second quarter of 2026.
- Knee products accounted for $829 million in net sales during the second quarter, increasing 0.4%.
- Hip products accounted for $563 million in net sales, growing 5%.
- Sports medicine, extremities, trauma, craniomaxillofacial and thoracic products accounted for $586 million in net sales, climbing 6.4%.
- Technology and data, bone cement and surgical products accounted for $199 million in net sales, a jump of 21.1%.
- Zimmer Biomet’s net sales for the first half of 2026 totaled $4.26 billion, an increase of 7% compared to the first half of 2025.
- Net earnings for the second quarter of 2026 were $198 million.
- The company raised its full-year 2026 revenue guidance from a range of 2.5% to 4.5% to a new range of 3.9% to 4.9%.
- Zimmer Biomet’s next-generation ROSA Shoulder System received FDA clearance in May.
- The company is planning to repurchase up to $1 billion of its common stock during fiscal year 2026.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.